UK health tech company Medopad has announced its first acquisition as it accelerates its expansion into the United States.

Medopad has acquired Sherbit, a Silicon Valley artificial intelligence start-up that works with the largest US healthcare systems to improve chronic disease patient care.

Medopad’s technology connects patients with healthcare professionals, allowing them to analyse a patient's data and detect life-threatening medical conditions.

It works with Royal Free London, Guy’s and St Thomas’, Bart’s, Chelsea & Westminster in the UK and is working on projects in counties including China, Germany and Singapore.

Named as a $1 billion HealthTech business in the making by KPMG, it says it is aiming to extend the lives of a billion people worldwide.

“At Medopad we want to create a world where people can live longer. We are working with some of the biggest companies in the world to improve the way doctors care for their patients by monitoring them at home and spotting any complications before they arise,” said Medopad CEO and founder Dan Vahdat.

“We are expanding rapidly across the world and acquiring Sherbit is just the first step for us in the US. 

“Sherbit has a strong track record of success working with some of the most prestigious healthcare organisations in the US, including the Mayo Clinic, Tufts Medical Center and Jefferson Health.

“Through this acquisition, Medopad will provide its technology to support solutions across different disease areas from rare diseases to chronic conditions.”

Sherbit CEO Alex Senemar said: “Sherbit and Medopad have the same vision to help people be healthier and live longer.

“We’re excited to leverage Medopad’s technology, clinical, and predictive analytics capabilities to expand what’s possible for our customers.”